本帖最后由 老马 于 2012-1-13 21:20 编辑
! M$ S& h; }9 w; T8 z. L6 b& T
9 ]+ e6 r9 e; A( I w4 d* ?爱必妥和阿瓦斯丁的比较 X A6 c3 d' }1 p9 Z9 l: a
3 o+ _$ x/ Z2 O/ x) o. y0 q% G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
. B$ o/ A% ?1 ?. K( e
: A" y2 c' q. L1 C. C
5 J. k0 g; s/ Q; W
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
2 E6 R6 T, L. e7 q( l==================================================, P# t# @3 \$ f( @' F" }
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) E. f' ^8 k$ h1 g9 ]% aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
I; J5 ~% | N# s' KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 z$ [* i( p" f+ y! v. R$ f8 Z
|